CY1107042T1 - Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων - Google Patents

Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων

Info

Publication number
CY1107042T1
CY1107042T1 CY20071101529T CY071101529T CY1107042T1 CY 1107042 T1 CY1107042 T1 CY 1107042T1 CY 20071101529 T CY20071101529 T CY 20071101529T CY 071101529 T CY071101529 T CY 071101529T CY 1107042 T1 CY1107042 T1 CY 1107042T1
Authority
CY
Cyprus
Prior art keywords
protein
adenylis
cyclas
recombinated
brought
Prior art date
Application number
CY20071101529T
Other languages
English (en)
Inventor
Xavier-Edmond-Edouard Preville
Claude Leclerc
Daniel Ladant
Benedikt Timmerman
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of CY1107042T1 publication Critical patent/CY1107042T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση σχετίζεται με μια ανασυνδυασμένη πρωτεΐνη που αποτελείται από ένα ή περισσότερα πολυπεπτίδια που φέρουν έναν ή περισσότερους επιτόπους ενός ή περισσοτέρων αντιγόνων του HPV, όπου τα αναφερθέντα πολυπεπτίδια έχουν εισαχθεί στην ίδια ή διαφορετικές επιτρεπόμενες θέσεις μιας πρωτεΐνης αδενυλικής κυκλάσης (CyaA) ή ενός τμήματος αυτής, όπου τα τμήματα της αναφερθείσας CyaA διατηρούν τις ιδιότητες της αναφερθείσας πρωτεΐνης αδενυλικής κυκλάσης στο να στοχεύουν Αντιγονοπαρουσιαστικά Κύτταρα. Επίσης αφορά πολυνουκλεοτίδια που κωδικοποιούν τις ίδιες πρωτεΐνες. Η ανασυνδυασμένη πρωτεΐνη ή το πολυνουκλεοτίδιο μπορούν να χρησιμοποιηθούν για τον σχεδιασμό θεραπευτικών μέσων έναντι των μολύνσεων από HPV ή έναντι των κακοηθών επιπτώσεων του.
CY20071101529T 2004-03-18 2007-11-29 Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων CY1107042T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04290741A EP1576967B1 (en) 2004-03-18 2004-03-18 Recombinant protein, carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof, therapeutic uses thereof

Publications (1)

Publication Number Publication Date
CY1107042T1 true CY1107042T1 (el) 2012-09-26

Family

ID=34833798

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101529T CY1107042T1 (el) 2004-03-18 2007-11-29 Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων

Country Status (19)

Country Link
US (3) US8628779B2 (el)
EP (3) EP1576967B1 (el)
JP (2) JP5438897B2 (el)
KR (2) KR101382250B1 (el)
CN (1) CN1956730B (el)
AT (1) ATE372784T1 (el)
AU (1) AU2005224036B2 (el)
BR (1) BRPI0508722A (el)
CA (1) CA2559235C (el)
CY (1) CY1107042T1 (el)
DE (1) DE602004008874T2 (el)
DK (1) DK1576967T3 (el)
ES (1) ES2293178T3 (el)
MX (1) MXPA06010469A (el)
PL (1) PL1576967T3 (el)
PT (1) PT1576967E (el)
RU (1) RU2441022C2 (el)
SI (1) SI1576967T1 (el)
WO (1) WO2005089792A1 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
PL1576967T3 (pl) 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
HUE027894T2 (en) * 2006-03-27 2016-11-28 Univ California An androgen receptor modulator for the treatment of prostate cancer and androgen receptor related diseases
EP1894941A1 (en) * 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
US9486524B2 (en) 2006-09-01 2016-11-08 Genticel Composition for eliciting a specific CTL response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells
ES2496916T3 (es) 2007-05-31 2014-09-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Epítopo de HPV al que se dirigen células T que infiltran tumores malignos cervicales para su uso en vacunas
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
CA2694457A1 (en) * 2007-07-24 2009-01-29 Ingrid Jolanda Monique De Vries Compositions and methods for generating an immune response in a subject
CN102439146A (zh) * 2009-03-23 2012-05-02 巴斯德研究院 适合将免疫原性分子递送到细胞中的突变CyaA多肽及多肽衍生物
US20120237535A1 (en) * 2009-09-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Therapeutic Compositions For The Treatment of HPV-Induced Diseases
WO2012006727A1 (en) * 2010-07-15 2012-01-19 British Columbia Cancer Agency Branch Human papillomavirus e7 antigen compositions and uses thereof
EP2478915A1 (en) 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
WO2012172042A1 (en) 2011-06-17 2012-12-20 Universiteit Gent Vaccines for chlamydia
DK2793937T3 (da) * 2011-12-21 2019-07-01 Vaccibody As Vacciner mod HPV
EP2687849A1 (en) * 2012-07-20 2014-01-22 ISA Pharmaceuticals B.V A process for providing an optimized immune therapy composition
EP2690172A1 (en) 2012-07-23 2014-01-29 Genticel CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
EP2689786A1 (en) 2012-07-23 2014-01-29 Genticel HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders
WO2015018943A2 (en) * 2013-08-08 2015-02-12 Institut Pasteur Correlation of disease activity with clonal expansions of human papillomavirus 16-specific cd8+ t-cells in patients with severe erosive oral lichen planus
EP2975120A1 (en) * 2014-07-17 2016-01-20 Institut Pasteur Monomeric and functional adenylate cyclase CyaA toxin
US10420826B2 (en) 2014-11-11 2019-09-24 Massachusetts Eye & Ear Infirmary Conjunctivitis vaccines
EP3037103A1 (en) 2014-12-23 2016-06-29 Genticel Immunotherapeutic vaccine comprising E7 proteins of HPV16 and HPV18 fused with CyaA, for use in subjects infected with HPV
US11001830B2 (en) * 2015-03-16 2021-05-11 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Method of detecting new immunogenic T cell epitopes and isolating new antigen-specific T cell receptors by means of an MHC cell library
RU2743016C2 (ru) * 2016-06-07 2021-02-12 Дойчес Кребсфоршунгсцентрум Улучшение иммуногенности пептида l2 впч
WO2018091613A1 (en) 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3323426A1 (en) 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3342421A1 (en) 2016-12-27 2018-07-04 Genticel Immunogenic composition comprising cyaa-derived polypeptide promoting a th1/th17-oriented immune response
JP7423554B2 (ja) * 2018-05-30 2024-01-29 ドイチェス クレブスフォルシュンクスツェントルム 予防用及び治療用の組み合わせワクチン
WO2021063917A1 (en) 2019-10-01 2021-04-08 Universiteit Gent Vaccine against chlamydia in swine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015044A1 (de) * 1990-05-10 1991-11-14 Behringwerke Ag Seroreaktive epitope auf proteinen des menschlichen papillomavirus (hpv) 18
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US6183745B1 (en) 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
EP0637335B1 (en) * 1992-04-21 2007-07-25 Institut Pasteur Recombinant mutants for inducing specific immune responses
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
WO2003009812A2 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
EP1489092A1 (en) 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
WO2005053738A1 (en) 2003-11-21 2005-06-16 Institut Pasteur Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
PL1576967T3 (pl) 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
EP1894941A1 (en) 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
DK2233569T3 (da) 2009-03-23 2014-10-06 Inst Of Microbiology Of The Ascr V V L Mutante CyaA-polypeptider og polypeptidderivater egnet til at levere immunogene molekyler i en celle

Also Published As

Publication number Publication date
EP2351580B1 (en) 2017-09-20
JP2007533307A (ja) 2007-11-22
DE602004008874D1 (de) 2007-10-25
EP1725259B1 (en) 2018-02-21
CN1956730A (zh) 2007-05-02
EP1576967A1 (en) 2005-09-21
WO2005089792A1 (en) 2005-09-29
RU2006131598A (ru) 2008-04-27
JP5824474B2 (ja) 2015-11-25
ES2293178T3 (es) 2008-03-16
PT1576967E (pt) 2007-12-03
CA2559235A1 (en) 2005-09-29
US8637039B2 (en) 2014-01-28
EP2351580A1 (en) 2011-08-03
MXPA06010469A (es) 2007-07-04
KR101495740B1 (ko) 2015-02-25
RU2441022C2 (ru) 2012-01-27
US20140227308A1 (en) 2014-08-14
ATE372784T1 (de) 2007-09-15
SI1576967T1 (sl) 2008-02-29
US20110171244A1 (en) 2011-07-14
JP2013176390A (ja) 2013-09-09
BRPI0508722A (pt) 2007-08-14
CN1956730B (zh) 2012-04-25
EP1576967B1 (en) 2007-09-12
JP5438897B2 (ja) 2014-03-12
AU2005224036B2 (en) 2011-10-20
KR20130079671A (ko) 2013-07-10
DE602004008874T2 (de) 2008-06-12
KR101382250B1 (ko) 2014-04-24
EP1725259A1 (en) 2006-11-29
US20070072266A1 (en) 2007-03-29
DK1576967T3 (da) 2008-01-21
KR20070031889A (ko) 2007-03-20
AU2005224036A1 (en) 2005-09-29
CA2559235C (en) 2015-06-16
US8628779B2 (en) 2014-01-14
US9387243B2 (en) 2016-07-12
PL1576967T3 (pl) 2008-03-31

Similar Documents

Publication Publication Date Title
CY1107042T1 (el) Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων
WO2008026071A3 (en) Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying hpv antigens
EA201100072A1 (ru) Новые композиции и способы
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
ATE486890T1 (de) Ephb-rezeptorbindende peptide
AR064458A1 (es) Antagonistas especificos de vegf para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadios tempranos
CY1118153T1 (el) Αγωγη μικροβιακων μολυνσεων
EA201100071A1 (ru) Новые композиции и способы
HK1126856A1 (en) Methods for identifying polypeptide targets
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
WO2005012350A3 (en) Epha2 t-cell epitope agonists and uses therefor
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
HK1097854A1 (en) Surface-located campylobacter jejuni polypeptides
BRPI0518571A2 (pt) peptÍdeos de alfa timosina como adjuvantes de vacina contra cÂncer
ATE402956T1 (de) Neue, mhc klasse ii assoziierte peptide
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
RS20050577A (en) Compositions and methods for treating cancer using igsf9 and liv-1
ATE450272T1 (de) Rekombinantes adenylat-cyclase-toxin von bordetella induziert t-zell-antworten gegen tumorale antigene
ATE480552T1 (de) Stq-peptide
ATE525401T1 (de) Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene
EA202092966A1 (ru) Способы улучшения ответа на лечение с помощью антитела к lif у индивидуумов, страдающих от рака
WO2006097642A3 (fr) Composition comprenant la region n-terminale d'histone h2b de leishmania - utilisation pour induire une reponse immunitaire
RU2008149816A (ru) Рекомбинантный иммуноген для иммунизации против белка р17 вируса иммунодефицита человека